Skip to main content

Valeant Pharmaceuticals'


shares rose 2.4% to $17.74 after it announced a partnership with

Jazz Pharmaceuticals

involving its Xyrem treatment for narcolepsy patients.

Under the deal, Valeant receives Canadian marketing rights to the drug for an upfront payment as well as payments based on future sales in Canada. Xyrem should be available to patients there in mid-2007.


(AZN) - Get Astrazeneca PLC Sponsored ADR Report

shares gained 2.6% to $56.49 after Bear Stearns upgraded the stock to outperform from peer perform with a $64 price target.

Negative trial data on its proposed stroke drug NXY-059 and patent challenges involving reflux drug Nexium and antipsychotic Seroquel are weighing on the stock, but the analyst sees upside in the company's partnership with

Bristol-Myers Squibb

(BMY) - Get Bristol-Myers Squibb Company Report

to help promote and develop two type 2 diabetes drugs.

Stem-cell stocks took a hit Friday after the House of Representatives passed a bill to expand funding of embryonic stem cell research but fell short of the two-thirds vote needed to override a Bush veto.

Shares of


TheStreet Recommends


sank 9.3% to $3.04,

Aastrom Biosciences


fell 8.2% to $1.34,


( VIAC) slid 2.7% to $5.70, and


(GERN) - Get Geron Corporation Report

sank 2.5% to $8.68.

Shares of

Catalyst Pharmaceutical Partners

(CPRX) - Get Catalyst Pharmaceuticals, Inc. Report

gained 2% to $4 after the company said it added Dr. Thomas Kosten, a specialist in the treatment of drug addiction, to its scientific advisory board.

Among other health stocks winner Friday were


( NTMD), gaining 21.3% to $2.96;

Biogen Idec

(BIIB) - Get Biogen Inc. Report

; 1.1% higher to $50.98;

Vertex Pharmaceuticals

(VRTX) - Get Vertex Pharmaceuticals Incorporated Report

, up 4.1% to $37.54;


( ZGEN), rising 8.3% to $16.26; and

BioDelivery Sciences International

(BDSI) - Get BioDelivery Sciences International, Inc. Report

, up 12.6% to $3.04.

Among the losers were


( NRMX), falling 2.9% to $17.96;

Mylan Laboratories

(MYL) - Get Mylan N.V. (MYL) Report

, down 1.3% to $20.59;



, sinking 3.7% to $11.82; and


( SKYE), off 1.3% to $4.55.